Envisia Therapeutics Announces Presentation At J.P. Morgan Healthcare Conference
- Recent Positive Initial Phase 2 Clinical Data for ENV515 to be Highlighted during Conference Presentation -
- Recent Positive Initial Phase 2 Clinical Data for ENV515 to be Highlighted during Conference Presentation -
RESEARCH TRIANGLE PARK, N.C., Jan. 5, 2016 /PRNewswire/ -- Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today announced that Dr. Benjamin Yerxa will present at the 34th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2016 at 8:30 am local time in San Francisco, CA.
| Event: |
34th Annual J.P. Morgan Healthcare Conference |
| Date: |
Tuesday, January 12, 2016 |
| Time: |
8:30 am PT / 11:30 am ET |
In his presentation, Dr. Yerxa will highlight recent results from the Company's phase 2 clinical trial with ENV515 in patients with glaucoma. ENV515 is a fully biodegradable PRINT® particle formulation of a marketed prostaglandin analog that has the potential to lower intraocular pressure (IOP) for more than 6 months from a single dose. ENV515 has the potential to address the issue of poor patient compliance that exists today with daily eye drops and limit the progression of glaucoma that sometimes leads to vision loss.
Envisia is also leveraging the company's unique platform technology to develop products for other leading ocular diseases including age-related macular degeneration (AMD), diabetic macular edema (DME), and ocular inflammation.
ABOUT ENVISIA THERAPEUTICS™
Envisia Therapeutics is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® technology platform to develop therapies for a variety of ocular conditions, beginning with ENV515 for glaucoma. ENV515 is a novel, extended-release formulation of a marketed prostaglandin analogue with the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is actively exploring the use of the company's unique technology to develop products for other important ocular diseases including age-related macular degeneration (AMD), diabetic macular edema (DME), and ocular inflammation. Envisia is located in Research Triangle Park, North Carolina. For more information, please go to www.envisiatherapeutics.com.
Logo - http://photos.prnewswire.com/prnh/20151006/274300LOGO
SOURCE Envisia Therapeutics
Share this article